Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLYNx
- Development stage
- Preclinical
- Lead developer
- Neurobio.ai
- Modality
- Small Molecules
01
Overview
GLYNx is a preclinical drug discovery program developed by NeuroBio.ai, targeting Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The program utilizes the proprietary GLYNx AI platform, which leverages graph neural networks and explainable artificial intelligence to identify novel therapeutic targets and optimize small molecule candidates. Currently in the discovery phase, the program aims to address the underlying biological drivers of neurodegeneration. While the specific molecular targets remain proprietary, the platform is designed to navigate the complex pathology of ALS and FTD to find high-affinity drug-target pairs.
- Other names
- GLYNx ALS/FTD program
Beyond the preview
Go deeper on GLYNx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLYNx.